Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 16,413.20 4.66 0.03%
S&P 500 1,864.59 -0.26 -0.01%
NASDAQ 4,095.02 -0.50 -0.01%
Ticker Volume Price Price Delta
STOXX 50 3,155.81 16.55 0.53%
FTSE 100 6,625.25 41.08 0.62%
DAX 9,409.71 91.89 0.99%
Ticker Volume Price Price Delta
NIKKEI 14,512.38 -3.89 -0.03%
TOPIX 1,171.40 -1.97 -0.17%
HANG SENG 22,760.24 64.23 0.28%

MyoKardia Appoints Tassos Gianakakos to Chief Executive Officer



  MyoKardia Appoints Tassos Gianakakos to Chief Executive Officer

Business Wire

SOUTH SAN FRANCISCO, Calif. -- October 30, 2013

MyoKardia, Inc., a company focused on developing innovative therapeutics to
treat genetic heart disease, today announced the appointment of Tassos
Gianakakos to chief executive officer. Mr. Gianakakos succeeds founding CEO
Charles Homcy, M.D., who will remain on MyoKardia’s board of directors.

“I am delighted to welcome Tassos to the MyoKardia team given his track record
of growing and transforming research-stage organizations with meaningful drug
platforms into clinical and commercial-stage companies,” said Dr. Homcy, who
is also a venture partner at Third Rock Ventures. “Tassos is a proven industry
leader with deep scientific, financial, operational and business development
experience, which will be invaluable to MyoKardia as the team continues to
develop our platform targeting genetic heart disease and rapidly advance our
lead cardiomyopathy program toward the clinic.”

Mr. Gianakakos brings more than 17 years of broad-based biopharmaceutical
expertise to MyoKardia. He joins the company from MAP Pharmaceuticals
(acquired by Allergan in March 2013) where he was most recently senior vice
president and chief business officer. Prior to MAP, Mr. Gianakakos led the
formation of Codexis, Inc., where he served as president and senior vice
president, business development, and global head of Codexis' Pharmaceuticals
Business Unit. Before forming Codexis, Mr. Gianakakos was director of business
development at Maxygen, where he led the company’s business development
efforts for its vaccine and bio-industrial platforms. Prior to Maxygen, Mr.
Gianakakos was a process engineer in Merck & Co.’s vaccine division. Mr.
Gianakakos holds B.Sc. degrees in chemical engineering and economics from the
Massachusetts Institute of Technology, an M.Sc. in biotechnology from
Northwestern University and an M.B.A. from Harvard Business School.

“MyoKardia is pioneering a revolutionary new approach to developing
cardiovascular therapies for patients who desperately need them,” said Mr.
Gianakakos. “By bringing together recent scientific breakthroughs in
cardiovascular genetics, muscle biology and biophysics, we target the disease
at its source, truly transforming the way cardiomyopathies and other
heart-related conditions will be treated. I am thrilled to join the MyoKardia
team and work with our exceptional and incredibly passionate scientists and
renowned founders to pave the way for a truly personalized approach for
patients with genetic heart disease.”

Genetic cardiomyopathies are conditions that arise from mutations in critical
heart muscle proteins. Dilated and hypertrophic cardiomyopathies (DCM and HCM)
are the most common forms of heart muscle disease and the most common
diagnosis leading to cardiac transplantation. More than 60 million people
worldwide have a cardiomyopathy or carry a cardiomyopathy gene mutation,
including approximately 1 million patients in the U.S.

About MyoKardia, Inc.

MyoKardia is dedicated to revolutionizing the treatment of genetic heart
disease. The company’s proprietary platform combines recent breakthroughs in
muscle biology with leading-edge cardiovascular disease genetics. This
personalized, genetically targeted approach focuses on the underlying cause of
disease and has the potential to drastically improve the treatment of
cardiomyopathies, and ultimately a broader spectrum of cardiovascular disease,
including heart failure. Founded by world leaders in muscle biology and
cardiovascular disease genetics, MyoKardia was launched in 2012 with funding
from leading life sciences investor, Third Rock Ventures. For more
information, please visit www.myokardia.com.

Contact:

Pure Communications
Katie Wilson, 910-509-3977
katie@purecommunicationsinc.com
Sponsored Links
Advertisement
Advertisements
Sponsored Links
Advertisement